Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection

BACKGROUND: This international, phase 2, open-label, multicenter study (ClinicalTrials.gov Identifier: NCT01609933) was conducted to evaluate the safety and efficacy of an enhanced regimen consisting of the direct-acting antivirals (DAAs) ombitasvir, paritaprevir, and ritonavir administered for 24 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernstein, David, Tripathi, Rakesh, Cohen, Daniel E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386203/
https://www.ncbi.nlm.nih.gov/pubmed/30858739
http://dx.doi.org/10.2147/HMER.S189158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386203/
https://www.ncbi.nlm.nih.gov/pubmed/30858739
http://dx.doi.org/10.2147/HMER.S189158

Ejemplares similares